Pharmacogenetics in the treatment of breast and ovarian cancer patients Peter A. Fasching UCLA David Geffen School of Medicine Div. Hem/Onc.

Slides:



Advertisements
Similar presentations
Lecture 45 Prof Duncan Shaw. Applications - finding genes Currently much interest in medical research, in finding the genes causing disease Sometimes.
Advertisements

Lecture 2 Strachan and Read Chapter 13
Pharmacogenetics of Phase II Drug Metabolizing Enzymes Richard Weinshilboum, PI 1, Eric Wieben, Co-PI 1, Aman Buzdar 2, Christopher Chute 1, Julie Cunningham.
Understanding Genome-Wide Profiling of Cancer
CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
James R. Rigas Comprehensive Thoracic Oncology Program
Which Phenotypes Can be Predicted from a Genome Wide Scan of Single Nucleotide Polymorphisms (SNPs): Ethnicity vs. Breast Cancer Mohsen Hajiloo, Russell.
Genetic Analysis in Human Disease
Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
MiRNA Platform Overview The Agilent miRNA Microarray System A New Microarray-based Tool for Profiling Human miRNAs.
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Dr. Almut Nebel Dept. of Human Genetics University of the Witwatersrand Johannesburg South Africa Significance of SNPs for human disease.
Computational Tools for Finding and Interpreting Genetic Variations Gabor T. Marth Department of Biology, Boston College
Positional Cloning LOD Sib pairs Chromosome Region Association Study Genetics Genomics Physical Mapping/ Sequencing Candidate Gene Selection/ Polymorphism.
Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)
Memorial Sloan-Kettering Cancer Center
Multi-dimensional Genomic Profiling of Acute Leukemias Characterized by MLL gene rearrangements Eunice S. Wang MD (Medicine) and Norma J. Nowak PhD (Cancer.
Diabetes and Endocrinology Research Center The BCM Microarray Core Facility: Closing the Next Generation Gap Alina Raza 1, Mylinh Hoang 1, Gayan De Silva.
Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Pharmacogenomics and personalized medicines Jean-Marie Boeynaems
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!
Pharmacogenomics: Studies in Breast Cancer Lynn C. Hartmann MD Mayo Clinic Cancer Center.
Genetic Analysis in Human Disease. Learning Objectives Describe the differences between a linkage analysis and an association analysis Identify potentially.
Molecular Biomarkers in Radiotherapy of Cervical Cancer A collaboration project between Department of Gynecologic Oncology and Department of Radiation.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Predictive Biomarkers for Lung Cancer Current Status / Perspectives: Although curative resection of patients with early-stage lung CA are performed, the.
ARC Biotechnology Platform: Sequencing for Game Genomics Dr Jasper Rees
The medical relevance of genome variability Gabor T. Marth, D.Sc. Department of Biology, Boston College
Analyzing DNA Differences PHAR 308 March 2009 Dr. Tim Bloom.
Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial.
Pharmacogenomics Eric Jorgenson.
Utilizing Science & Technology and Innovation for Development A Genome Wide Association Study for Type 2 Diabetes Susceptibility Gene and Treatment in.
Computational research for medical discovery at Boston College Biology Gabor T. Marth Boston College Department of Biology
Prognose mittels Genexpression Prof. Martin H. Brutsche Kantonsspital St. Gallen-CH.
BIOMARKERS Diagnostics and Prognostics. OMICS Molecular Diagnostics: Promises and Possibilities, p. 12 and 26.
Pharmacogenetics and Pharmacogenomics Eric Jorgenson 2/24/9.
©Edited by Mingrui Zhang, CS Department, Winona State University, 2008 Identifying Lung Cancer Risks.
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Wang Y 1,2, Damaraju S 1,3,4, Cass CE 1,3,4, Murray D 3,4, Fallone G 3,4, Parliament M 3,4 and Greiner R 1,2 PolyomX Program 1, Department.
A Genome-wide association study of Copy number variation in schizophrenia Andrés Ingason CNS Division, deCODE Genetics. Research Institute of Biological.
Genetic Repositories Australia BACKGROUND GRA supported by an NHMRC Enabling Facility Grant awarded in  GRA supported by an NHMRC Enabling Facility.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Copy Number Variation Eleanor Feingold University of Pittsburgh March 2012.
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
Lecture 6. Functional Genomics: DNA microarrays and re-sequencing individual genomes by hybridization.
Kathleen Giacomini, Mark J. Ratain, Michiaki Kubo, Naoyuki Kamatani, and Yusuke Nakamura NIH Pharmacogenomics Research Network III & RIKEN Center for Genomic.
Integrating Pharmacogenomic Questions Into GCIG Ovarian Cancer Clinical Trials Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research.
Computational Biology and Genomics at Boston College Biology Gabor T. Marth Department of Biology, Boston College
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
(1) Genotype-Tissue Expression (GTEx) Largest systematic study of genetic regulation in multiple tissues to date 53 tissues, 500+ donors, 9K samples, 180M.
Breast cancer Not a single disease. Type and stage. Grade/Lympho-vascular invasion Molecular biology. ER\PR Her-2-neu Other. Gene expression profiling.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,
1 Finding disease genes: A challenge for Medicine, Mathematics and Computer Science Andrew Collins, Professor of Genetic Epidemiology and Bioinformatics.
Pharmacogenetics/Pharmacogenomics. Outline Introduction  Differential drug efficacy  People react differently to drugs Why does drug response vary?
Multi-scale network biology model & the model library 多尺度网络生物学模型 -- 兼论模型库的建立与应用 Jianghui Xiong 熊江辉
Gene Hunting: Design and statistics
Genomes and Their Evolution
Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers.
The Genetic Basis for Cancer Treatment Decisions
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Presentation transcript:

Pharmacogenetics in the treatment of breast and ovarian cancer patients Peter A. Fasching UCLA David Geffen School of Medicine Div. Hem/Onc

Concepts of science Therapy ATherapy B Therapy A must be better 2

Pitfalls with this approach Will this patient have a recurrence? Therapie A A: Therapy helped, and the patient has no recurrence. B: Patient would not have gotten a recurrence anyway 3

Aim A priori identification of patients with a benefit from the offered therapy Test Therapy will improve outcome Therapy will NOT improve outcome 4

Gene expressions From stromal cells Gene expression profiles SNP Chips (Germline-DNA) Gene expression Profiling (WBC) Epigenetic Profiling (circulating nucleic acids) Gene copy variations Epigentic Profiling Mutation Profiling Proteomics Biomaterials that could be helpful miRNA Profiling 5 miRNA Profiling

SNP Chips (Germline-DNA) Biomaterials that could be helpful 6 Can predict: -Efficacy -Toxicity Can discover: -functional explanation of differential response to chemotherapy

Tamoxifen-Metabolism 7

CYP2D6 Genotyping as a predictive marker (Schroth, Goetz, Hamann, Fasching et al. JAMA 2009) N=1325 ER positive Breast Cancer Patients All treated with Tamoxifen Genotyping CYP2D6 *3, *4, *5, *10, *41 Metabolizing Groups EM=extensive Metabolizers IM=Intermediate Metabolizers PM=Poor Metabolizers 8

The genome wide approach

How many Single nucleodide Polymorphisms are out there? About 3.3 Billion base pairs about 24,000 genes

Persons genotyped SNPsPolymorphic 1(20) + 2 or so??? 24010,000,0003,100, >15,000,000>???? / 2010 How many Single nucleodide Polymorphisms are out there? Image Source: The Sanger Institute >1,000,000 SNPs to be analyzed by chip technology on one chip

How to analyze and present 1,000,000 associations between genetic variations and the phenotype? SNP1 (Chr1) Genotype 1Genotype 2 Phenotype 110%50% Phenotype 290%50% SNP2 (Chr1) Genotype 1Genotype 2 Phenotype 110% Phenotype 290% SNP3 (Chr1) Genotype 1Genotype 2 Phenotype 110%20% Phenotype 290%80% P=0, P=0,9 P=0,001

How can I present a million associations?

P=1 P=0,1 P=0,0001 P=0,001 P=0,01 P=0,00001

-log10(p-value) Conditional Logistic Regression Analyses* Ingle et al. San Antonio 2010 Chromosome Position

How to do the work?  Clinical collaborators with well designed studies(!!!)  Biosampling infrastructure  Genotyping Facility  Biostatistics/Bioinformatics  Functional Explanation  Clinical collaborators for clinical validation

R E C DcT SUCCESS A Study: Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment Surveillance-Trial (n=3725) (PI: Prof. Dr. W. Janni) DcT E C =Docetaxel =Epirubicin =Cyclophosphamide F E C F E C F E C DcT F E C F E C F GGG G =Gemcitabine F = 5-Flourouracil Primary Objective Disease free Survival Secondary Objectives Overall Survival, Toxicity, Quality of Life R Zoledronate 2 years Zoledronate 5 years 21

Pre-planned Pharmacogenetic subprotocol 3602 out of 3754 patients (96%) provided DNA Samples (just one blood tube!!) Collaborative application of Mayo Clinics (PI Dr. Weinshilboum) and SUCCESS Study Group (Co-PI Dr. Fasching) for NIH funding NHGRI HG01 granted as part of a funding program for genome wide association studies for randomized trials

Structures for this collaboration Blood Processing DNA Extraction DNA Normalization DNA Plating Data Management Data entry Data Monitoring Data updates Genotyping Plate Map Design Genotype Quality Control DNA Storage Biostatistics Phenotype Quality Control Gx and Phx Data Cleaning Provision of Analysis DNA Analysis SNP Chip Processing Coordination Collboration with other Groups Working groups on Phenotype HarmonizationPhenotype Harmonization Genotype HarmonizationGenotype Harmonization Statistical MethologyStatistical Methology Ethical ConsiderationsEthical Considerations Cross ValidationCross Validation Further Clinical ValidationFurther Clinical Validation Clinical Collaborators SUCCESS A Study (GeparQuinto Study) Mayo Collaborators PGRN Biostatistics Molecular Pharmacology Hematology / Oncology Genotype Core Facility Cell Line Program Human Variation Panel BC Panel (UCLA) NIH NHGRI GARNET (

Structures for this collaboration Blood Processing DNA Extraction DNA Normalization DNA Plating Data Management Data entry Data Monitoring Data updates Genotyping Plate Map Design Genotype Quality Control DNA Storage Biostatistics Phenotype Quality Control Gx and Px Data Cleaning Provision of Analysis DNA Analysis SNP Chip Processing Coordination Collboration with other Groups Working groups on Phenotype HarmonizationPhenotype Harmonization Genotype HarmonizationGenotype Harmonization Statistical MethologyStatistical Methology Ethical ConsiderationsEthical Considerations Cross ValidationCross Validation Further Clinical ValidationFurther Clinical Validation Clinical Collaborators SUCCESS A Study (GeparQuinto Study) Mayo Collaborators Biostatistics Molecular Pharmacology Hematology / Oncology Genotype Core Facility Cell Line Program Human Variation Panel BC Panel (UCLA) NIH NHGRI GARNET (

Genome-wide SNPs: Affy 6.0 and Illumina 550S and 510S. 1.3 million SNPs Expression array: Affy U133 Plus2.0, 54,000 probe sets Exon array microRNA CNV data In-depth gene resequencing data Mayo PGRN - “Human Variation Panel” Cell Lines UCLA – Human Individual Breast Cancer Cell Lines MAYO lymphoblastoid Cell lines (Dr Wang) UCLA - 52 Breast Cancer Cell lines (Dr Finn) Genome-wide SNPs: Illumina 610K Expression array: Agilent Human 44k CNV Data 25

Where do we stand with Ovarian Cancer? The Ovarian Cancer Association Consortium CoordinatingCenters Duke University, USA, USC (L.A.), USA Cambridge, UK 8 US Sites 4 Australian Sites 1 Asian Site 12 European Sites 1 South American Site 1 African Site 26,000 Ovarian cancer patients with germline DNA26,000 Ovarian cancer patients with germline DNA Epidemiological dataEpidemiological data Clinical data, Therapy dataClinical data, Therapy data Follow Up dataFollow Up data Tissue Microarray with >9,000 SamplesTissue Microarray with >9,000 Samples 31,000 Healthy Controls31,000 Healthy Controls Epidemiological DataEpidemiological Data

Call for Data and sample pooling for drug/genotype Interactions Behaviour Primary Site Sub Type Stage Histopathological grade Miliary Disase Residual Disease First Line Chemotherapy  Duration Chemotherapy  Dose Chemotherapy Progression (RECIST OR GCIG) Death

SiteCountryCasesChemo AOCSAustralia600Platinum/taxane MALOVADenmark680Mostly pre-taxanes LOS ANGELESUSA360Platinum/taxane MAYOUSA466Platinum/taxane BAVARIAGermany271Platinum/taxane LEUVENBelgium296Platinum/taxane RPC235Platinum/taxane YALEUSA96Platinum/taxane PVD203Platinum/taxane SCOTROC1GB950Platinum/taxane GOGUSA493Platinum/taxane TOTAL3970Platinum/taxane Work in Progress: Sets for analysis of PFS and Genotype

What would be future questions Dramatically increase sample size for genomewide studies Important Questions within randomized clinical trials